|
|
Slovenia Pharmaceuticals and Healthcare Report Q2 2008Published by: Business Monitor International Published: Apr. 24, 2008 - 60 Pages Table of Contents
AbstractDespite being smaller and more mature than most of its Central and Eastern European (CEE) peers,Slovenia still offers considerable commercial opportunities within its pharmaceutical market. Most of thegrowth over the coming years is set to be driven by the introduction and use of more advanced treatments,despite the government’s attempt to control pharmaceutical spending by placing limits on prescribing andsimilar measures. In addition, the fact that most branded generics enjoy relatively high prices in relationto original products will support this upward trend.In the meantime, the high incomes of a substantial proportion of the population will also be positivelyreflected in the growth of the over-the-counter (OTC) segment, especially as consumers become morehealth conscious. The government’s programme for reducing the use of hospitals, as well as an attempt toaddress overprescribing, will also result in the development of the OTC market. The Slovenian medical devices market is relatively advanced in relation to its CEE peers. Furthercommercial opportunities are provided by the country’s wealth, healthcare system modernisation andrising patient demands. While imports have traditionally dominated the medical devices landscape,exports have recorded strong growth in recent years, with the main destinations being the territories of theformer Yugoslavia. In BMI’s adjusted Business Environment Rankings for Q208, Slovenia slipped from joint sixth to jointeighth position, which it now occupies alongside Romania. The country’s ranking is negatively affectedby its limited population number, negligible population growth and the country’s inadequate IP laws. Onthe other hand, the expansive private insurance coverage and established trade regimes with WesternEurope (boosted by the recent entry into the eurozone) allow for good placement of novel drugs onto themarket. Given the limitations of a saturated home market, Slovenia’s key pharmaceutical producers - namely Lekand Krka - are increasingly looking abroad for revenue. Lek’s activities have expanded following itstakeover by Sandoz, a generic arm of Swiss major Novartis, while in November 2007 Krka indicated achange in its strategy, which was previously focused on organic growth, by acquiring a German genericsfirm. Foreign firms are highly visible on the local market, but only through imports - bar Novartis. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||